

## *Onxeo Provides Update on Litigation with SpeBio/SpePharm*

**Paris (France), January 23, 2018 – 09:30 pm CET** - Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO FR0010095596), (“**Onxeo**” or the “**Company**”), a biotechnology company specializing in the development of innovative drugs in oncology, and notably rare and resistant forms of cancer, announces that it has submitted its conclusions to the Paris Court of Appeal concerning merits of the litigation against SpePharm/SpeBio B.V companies to ensure that the appeals process proceeds as expeditiously as possible for the benefit of its shareholders.

The Company will take all actions to convince the Court of Appeal of its legal position and the Court’s decision is expected as early as the end of Q4 2018.

In regards to the expected payment of the amounts determined by the Commercial Court of Paris on October 17, 2017, the Company is currently putting in place an action plan allowing to pursue its R&D programs as initially planned.

### **Next financial press release:**

2017 annual results: Thursday March 29, 2018, after market close.

### **About Onxeo**

Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a French biotechnology company developing innovative oncology drugs based on DNA-targeting and epigenetics, two of the most sought-after mechanisms of action in cancer treatment today. The Company is focused on bringing early-stage first-in-class or disruptive compounds (proprietary, acquired or in-licensed) from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

Onxeo’s R&D pipeline includes **belinostat**, an HDAC inhibitor (epigenetics) currently being developed in oral form to be used in combination with other anti-cancer agents for liquid or solid tumors. Belinostat is already conditionally FDA-approved in the US as a 2<sup>nd</sup> line treatment for patients with peripheral T cell lymphoma and marketed in the US by Onxeo’s partner, Spectrum Pharmaceuticals, under the name Beleodaq® (belinostat IV form).

Onxeo is also developing **AsiDNA™**, a first-in-class DNA break repair inhibitor based on a unique decoy mechanism. AsiDNA™ has already successfully completed a Phase I trial in metastatic melanoma via local administration, and is currently being developed for systemic (IV) administration in solid tumors.

AsiDNA™ is the first compound generated from **platON™**, the Company’s proprietary chemistry platform of decoy oligonucleotides based on three components, a sequence of double strand oligonucleotides, a linker and a cellular uptake facilitator. PlatON™ will continue to generate new compounds that will broaden Onxeo’s pipeline.

**For further information, please visit [www.onxeo.com](http://www.onxeo.com).**

### **Forward looking statements**

This communication expressly or implicitly contains certain forward-looking statements concerning Onxeo and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Onxeo to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Onxeo is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of Onxeo to differ from those contained in the forward-looking statements, please refer to the section 5.5.1.4



"Risk Factors" ("*Facteurs de Risque*") of the 2016 reference document filed with the *Autorité des marchés financiers* on April 24, 2017 under number D.17-0423, which is available on the *Autorité des marchés financiers* website ([www.amf-france.org](http://www.amf-france.org)) or on the Company's website ([www.onxeo.com](http://www.onxeo.com)).

**Onxeo**

Valerie Leroy,  
Investor Relations  
[investors@onxeo.com](mailto:investors@onxeo.com)  
+33 1 45 58 76 00

**Media Relations**

Caroline Carmagnol [alize-onxeo@alizerp.com](mailto:alize-onxeo@alizerp.com)  
+33 6 64 18 99 59

**Investor Relations / Strategic  
Communication**

Dušan Orešanský / Emmanuel Huynh  
NewCap  
[onxeo@newcap.eu](mailto:onxeo@newcap.eu)  
+33 1 44 71 94 92

**Investor Relations US**

Brian Ritchie  
LifeSci Advisors  
[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)  
+1 212 915 2578